Archives for April 10, 2005

← 2005

Data platform improves cancer data access

New web based software, which can extract potentially life-saving knowledge from data in minutes, has bioinformatic research applications that could prove essential to laboratory technicians wanting to improve diagnosis and treatment of cancer.

CO2 leak tester provides cost savings

Witt Gas Technologies has launched a new version of its Leak-Master packaging integrity tester in the UK that could pay for itself in terms of cost savings in as little as two months, claims the company.

Molecular Devices introduces two ADME screening assay kits

Molecular Devices launches two new reagent products for ADME assay screening, which provide high throughput screening laboratories with biologically relevant solutions to increase the throughput of ADME-related compound profiling.

Merck's HPV promising in Phase II trial

The prospect of a simple vaccination to prevent cervical cancer took a major step with the publication of positive Phase II trial results on a candidate from Merck, called Gardasil, in the April edition of the medical journal The Lancet Oncology.

New COX-2 scare as second painkiller withdrawn

The controversy over the COX-2 inhibitor class refuses to die down after the FDA asked Pfizer to withdraw Bextra (valdecoxib) from the market because the overall risk of heart disease and life-threatening skin reactions outweighed its therapeutic...

Schweizerhall's pharma expansion nears completion

Schweizerhall is well on the way to completing its acquisition of Cimex Pharma, and as a result completing the first stage of its transition to become a specialist supplier to the European generics industry, reports Phil Taylor.

CRO buys Xcelodose encapsulation system

Pfizer's recently acquired UK business Meridica has supplied the first Xcelodose automated encapsulator system to a contract research company in North America.

CFC ban will double albuterol inhaler market in US

The US Food and Drug Administration's decision to ban the use of chlorofluorocarbon propellants in albuterol metered-dose inhalers (MDIs) from the end of 2008 will effectively mean the market will revert to one of branded rather than generic drugs and...